Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases

Archivum Immunologiae et Therapiae Experimentalis

Volumn 52, Issue 1, 2004, Pages 13-26

  Gee, Katrina ^a   Kryworuchko, Marko ^a,b   Kumar, Ashok ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Autoimmunity; CD44; Cytokines; Hyaluronan; Inflammation

Indexed keywords

CELL ADHESION MOLECULE; HERMES ANTIGEN; HYALURONIC ACID; MEMBRANE PROTEIN;

AUTOIMMUNE DISEASE; CARCINOGENESIS; CELL MIGRATION; CELL TYPE; EXON; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LIGAND BINDING; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN PROCESSING; REVIEW; RNA SPLICING;

ALTERNATIVE SPLICING; ANIMALS; ANTIGENS, CD44; AUTOIMMUNE DISEASES; CELL ADHESION; CELL MOVEMENT; HUMANS; HYALURONIC ACID; INFLAMMATION; MICE; MICE, KNOCKOUT; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 4844228002     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Arch R., Wirth K., Hofmann M., Ponta H., Matzku S., Herrlich P. and Zoller M. (1992): Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science, 257, 682-685.
2. Ariel A., Novick D., Rubinstein M., Dinarello C. A., Lider O. and Hershkoviz R. (2002): IL-12 and IL-18 induce MAP kinase-dependent adhesion of T cells to extracellular matrix components. J. Leukoc. Biol., 72,192-198.
3. Bartolazzi A., Nocks A., Aruffo A., Spring F. and Stamenkovic I. (1996): Glycosylation of CD44 is implicated in CD44-mediated cell adhesion to hyaluronan. J. Cell Biol., 132, 1199-1208.
4. Bartolazzi A., Peach R., Aruffo A. and Stamenkovic I. (1994): Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J. Exp. Med., 180, 53-66.
5. Bechard D. E., Gudas S. A., Sholley M. M., Grant A. J., Merchant R. E., Fairman R. P., Fowler A. A. and Glauser F. L. (1989): Nonspecific cytotoxicity of recombinant interleukin-2 activated lymphocytes. Am. J. Med. Sci., 298, 28-33.
6. Bennett K. L., Modrell B., Greenfield B., Bartolazzi A., Stamenkovic I., Peach R., Jackson D. G., Spring F. and Aruffo A. (1995): Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. J. Cell Biol., 131, 1623-1633.
7. Bourguignon L. Y., Lokeshwar V. B., He J., Chen X. and Bourguignon G. J. (1992): A CD44-like endothelial cell transmembrane glycoprotein (GP116) interacts with extracellular matrix and ankyrin. Mol. Cell. Biol., 12, 4464-4471.
8. Brennan F. R., Mikecz K., Giant T. T., Jobanputra P., Pinder S., Bavington C., Morrison P. and Nuki G. (1997): CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro. Scand. J. Immunol., 45, 213-220.
9. Brocke S., Piercy C., Steinman L., Weissman I. L. and Veromaa T. (1999): Antibodies to CD44 and integrin α4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. USA, 96, 6896-6901.
10. + peripheral blood monocytes. J. Immunol., 167, 5367-5374.
11. Butcher E. C. and Picker L. J. (1996): Lymphocyte homing and homeostasis. Science, 272, 60-66.
12. Cairns A. P., Crockard A. D., McConnell J. R., Courtney P. A. and Bell A. L. (2001): Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann. Rheum. Dis., 60, 950-955.
13. Camacho F. I., Munoz C., Sanchez-Verde L., Saez A. I., Alcantara M. and Rodriguez R. (1999): CD44v6 expression in inflammatory bowel disease is associated with activity detected by endoscopy and pathological features. Histopathology, 35, 144-149.
14. Cichy J. and Pure E. (2000): Oncostatin M and transforming growth factor-β1 induce post-translational modification and hyaluronan binding to CD44 in lung-derived epithelial tumor cells. J. Biol. Chem., 275, 18061-18069.
15. Colombatti A., Hughes E. N., Taylor B. A. and August J. T. (1982): Gene for a major cell surface glycoprotein of mouse macrophages and other phagocytic cells is on chromosome 2. Proc. Natl. Acad. Sci. USA, 79, 1926-1929.
16. Cooper D. L., Dougherty G., Harn H. J., Jackson S., Baptist E. W., Byers J., Datta A., Phillips G. and Isola N. R. (1992): The complex CD44 transcriptional unit; alternative splicing of three internal exons generates the epithelial form of CD44. Biochem. Biophys. Res. Commun., 182, 569-578.
17. Dallaire M. J., Ferland C., Lavigne S., Chakir J. and Laviolette M. (2002): Migration through basement membrane modulates eosinophil expression of CD44. Clin. Exp. Allergy, 32, 898-905.
18. DeGrendele H. C., Estess P. and Siegelman M. H. (1997): Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science, 278, 672-675.
19. DeGrendele H. C., Kosfiszer M., Estess P. and Siegelman M. H. (1997): CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J. Immunol., 159, 2549-2553.
20. Delcommenne M., Kannagi R. and Johnson P. (2002): TNF-α increases the carbohydrate sulfation of CD44: induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans. Glycobiology, 12, 613-622.
21. + T cells. Immunol. Today, 11, 55-59.
22. Dougherty G. J., Landorp P. M., Cooper D. L. and Humphries R. K. (1991): Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells. J. Exp. Med., 174, 1-5.
23. Emlen W., Niebur J., Flanders G. and Rutledge J. (1996): Measurement of serum hyaluronic acid in patients with rheumatoid arthritis: correlation with disease activity. J. Rheumatol., 23, 974-978.
24. Endo K., Mizusawa N., Hirano H. and Shimamura T. (1998): Expression of CD44 variant isoforms in leukocytes of the joint fluid of rheumatoid arthritis patients and the effect of steroids. Methods Find. Exp. Clin. Pharmacol., 20, 709-717.
25. Estess P., DeGrendele H. C., Pascual V. and Siegelman M. H. (1998): Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J. Clin. Invest., 102, 1173-1182.
26. Fichter M., Hinrichs R., Eissner G., Scheffer B., Classen S. and Ueffing M. (1997): Expression of CD44 isoforms in neuroblastoma cells is regulated by PI 3-kinase and protein kinase C. Oncogene, 14, 2817-2824.
27. Finke L. H., Terpe H. J., Zorb C., Haensch W. and Schlag P. M. (1995): Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 345, 583.
28. Fiocchi C. (1998): Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology, 115, 182-205.
29. Fitzgerald K. A. and O'Neill L. A. (1999): Characterization of CD44 induction by IL-1: a critical role for Egr-1. J. Immunol., 162, 4920-4927.
30. Foster L. C., Wiesel P., Huggins G. S., Panares R., Chin M. T., Pellacani A. and Perrella M. A. (2000): Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1β in vascular smooth muscle cells. FASEB J., 14, 368-378.
31. Fujii K., Fujii Y., Hubscher S. and Tanaka Y. (2001): CD44 is the physiological trigger of fas up-regulation on rheumatoid synovial cells. J. Immunol., 167, 1198-1203.
32. Fujii K., Tanaka Y., Hubscher S., Saito K., Ota T. and Eto S. (1999): Cross-linking of CD44 on rheumatoid synovial cells up-regulates VCAM-1. J. Immunol., 162, 2391-2398.
33. Gal I., Lesley J., Ko W., Gonda A., Stoop R., Hyman R. and Mikecz K. (2003): Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow. J. Biol. Chem., 278, 11150-11158.
34. Galandrini R., De Maria R., Piccoli M., Frati L. and Santoni A. (1994): CD44 triggering enhances human NK cell cytotoxic functions. J. Immunol., 153, 4399-4407.
35. Galandrini R., Galluzzo E., Albi N., Grossi C. E. and Velardi A. (1994): Hyaluronate is costimulatory for human T cell effector functions and binds to CD44 on activated T cells. J. Immunol., 153, 21-31.
36. Galandrini R., Piccoli M., Frati L. and Santoni A. (1996): Tyrosine kinase-dependent activation of human NK cell functions upon triggering through CD44 receptor. Eur. J. Immunol., 26, 2807-2811.
37. Gee K., Kozlowski M. and Kumar A. (2003): TNF-α induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic cells. J. Biol. Chem., 278, 37275-37287.
38. Gee K., Lim W., Ma W., Nandan D., Diaz-Mitoma F., Kozlowski M. and Kumar A. (2002): Differential role of CD44 expression by LPS and TNF-α in human monocytic cells: Distinct involvement of C-jun-N-terminal kinase in LPS-induced CD44 expression. J. Immunol., 169, 5660-5672.
39. Gee K., Kozlowski M., Kryworuchko M., Diaz-Mitoma F. and Kumar A. (2001): Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells. Cell. Immunol., 211, 131-142.
40. Goldstein L. A. and Butcher E. C. (1990): Identification of mRNA that encodes an alternative form of H- CAM (CD44) in lymphoid and nonlymphoid tissues. Immunogenetics, 32, 389-397.
41. Goldstein L. A., Zhou D. F., Picker L. J., Minty C. N., Bargatze R. F., Ding J. F. and Butcher E. C. (1989): A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell, 56, 1063-1072.
42. Goodfellow P. N., Banting G., Wiles M. V., Tunnacliffe A., Parkar M., Solomon E., Dalchau R. and Fabre J. W. (1982): The gene, MIC4, which controls expression of the antigen defined by monoclonal anti-body F10.44.2, is on human chromosome 11. Eur. J. Immunol., 12, 659-663.
43. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A., Ponta H. and Herrlich P. (1991): A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65,13-24.
44. Haberhauer G. and Kittl E. M. (1998): Soluble CD44 isoform variant-5 (sCD44v5): a new serum marker in rheumatoid arthritis? J. Rheumatol., 25, 1442-1444.
45. Harn H. J., Isola N. and Cooper D. L. (1991): The multispecific cell adhesion molecule CD44 is represented in reticulocyte cDNA. Biochem. Biophys. Res. Commun., 178, 1127-1134.
46. Haynes B. F., Hale L. P., Patton K. L., Martin M. E. and McCallum R. M. (1991): Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum., 34, 1434-1443.
47. Herrlich P., Morrison H., Sleeman J., Orian-Rousseau V., Konig H., Weg-Remers S. and Ponta H. (2000): CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann. NY Acad. Sci., 910, 106-118; discussion 118-120.
48. Hofmann M., Rudy W., Zoller M., Tolg C., Ponta H., Herrlich P. and Gunthert U. (1991): CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res., 51, 5292-5297.
49. Hyman R. (2002): Lack of a consistent relationship between demethylation of the CD44 promoter and CD44 expression. Immunogenetics, 53, 914-924.
50. Ikehata A. and Tomichi N. (2000): CD44v6 expression in granuloma of Crohn's disease. Am. J. Gastroenterol., 95, 3325-3326.
51. Jackson D. G., Bell J. I., Dickinson R., Timans J., Shields J. and Whittle N. (1995): Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J. Cell Biol., 128, 673-685.
52. Jackson D. G., Buckley J. and Bell J. I. (1992): Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J. Biol. Chem., 267, 4732-4739.
53. Jalkanen S. and Jalkanen S. (1992): Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J. Cell Biol., 116, 817-825.
54. Johnson P., Maiti A., Brown K. L. and Li R. (2000): A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response? Biochem. Pharmacol., 59, 455-465.
55. Katoh S., Miyagi T., Taniguchi H., Matsubara Y., Kadota J., Tominaga A., Kincade P. W., Matsukura S. and Kohno S. (1999): Cutting edge: an inducible sialidase regulates the hyaluronic acid binding ability of CD44-bearing human monocytes. J. Immunol., 162, 5058-5061.
56. Kelleher D., Murphy A., Hall N., Omary M. B., Kearns G., Long A. and Casey E. B. (1995): Expression of CD44 on rheumatoid synovial fluid lymphocytes. Ann. Rheum. Dis., 54, 566-570.
57. Kito H., Suzuki H., Ichikawa T., Sekita N., Kamiya N., Akakura K., Igarashi T., Nakayama T., Watanabe M., Harigaya K. and Ito H. (2001): Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate, 49, 110-115.
58. Kittl E. M., Haberhauer G., Ruckser R., Selleny S., Rech-Weichselbraun I., Hinterberger W. and Bauer K. (1997): Serum levels of soluble CD44 variant isoforms are elevated in rheumatoid arthritis. Rheumatol. Int., 16, 181-186.
59. Koller M., Aringer M., Kiener H., Erlacher L., Machold K., Eberl G., Studnicka-Benke A., Graninger W. and Smolen J. (1999): Expression of adhesion molecules on synovial fluid and peripheral blood monocytes in patients with inflammatory joint disease and osteoarthritis. Ann. Rheum. Dis., 58, 709-712.
60. Koopman G., Heider K. H., Horst E., Adolf G. R., van den Berg F., Ponta H., Herrlich P. and Pals S. T. (1993): Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. Exp. Med., 177, 897-904.
61. Kryworuchko M., Diaz-Mitoma F. and Kumar A. (1999): Interferon-γ inhibits CD44-hyaluronan interactions in normal human B lymphocytes. Exp. Cell Res., 250, 241-252.
62. Kryworuchko M., Gee K., Diaz-Mitoma F. and Kumar A. (1999): Regulation of CD44-hyaluronan interactions in Burkitt's lymphoma and Epstein-Barr virus-transformed lymphoblastoid B cells by PMA and interleukin-4. Cell Immunol., 194, 54-66.
63. Ladeda V., Frankel P., Feig L. A., Foster D. A., Bal de Kier J. E. and Aguirre-Ghiso J. A. (2001): RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in N1H3T3 fibroblasts. Biochem. Biophys. Res. Commun., 283, 854-861.
64. Lamb R. F., Hennigan R. F., Turnbull K., Katsanakis K. D., MacKenzie E. D., Birnie G. D. and Ozanne B. W. (1997): AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell. Biol., 17, 963-976.
65. Legras S., Levesque J. P., Charrad R., Morimoto K., Le Bousse C., Clay D., Jasmin C. and Smadja-Joffe F. (1997): CD44-mediated adhesiveness of human hematopoietic progenitors to hyaluronan is modulated by cytokines. Blood, 89, 1905-1914.
66. Lesley J., English N., Charles C. and Hyman R. (2000): The role of the CD44 cytoplasmic and transmembrane domains in constitutive and inducible hyaluronan binding. Eur. J. Immunol., 30, 245-253.
67. Lesley J., English N., Perschl A., Gregoroff J. and Hyman R. (1995): Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation. J. Exp. Med., 182, 431-437.
68. Lesley J., Hyman R., English N., Catterall J. B. and Turner G. A. (1997): CD44 in inflammation and metastasis. Glycoconj. J., 14, 611-622.
69. Lesley J., Hyman R. and Kincade P. W. (1993): CD44 and its interaction with extracellular matrix. Adv. Immunol., 54, 271-335.
70. Levesque M. C. and Haynes B. F. (1997): Cytokine induction of the ability of human monocyte CD44 to bind Hyaluronan is mediated primarily by TNF-α and is inhibited by IL-4 and IL-13. J. Immunol., 159, 6184-6194.
71. Levesque M. C. and Haynes B. F. (1999): TNFα and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. Cell. Immunol., 193, 209-218.
72. Levesque M. C., Mackin D. A., Fleming J. A. and St Clair E. W. (2000): Serum levels of soluble CD44 in primary Sjogren's syndrome. J. Rheumatol., 27, 1444-1449.
73. Liu D., Liu T., Li R. and Sy M. S. (1998): Mechanisms regulating the binding activity of CD44 to hyaluronic acid. Front. Biosci., 3, D631-636.
74. Lokeshwar V. B., Fregien N. and Bourguignon L. Y. (1994): Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function. J. Cell Biol., 126, 1099-1109.
75. Lou W., Krill D., Dhir R., Becich M. J., Dong J. T., Frierson H. F. J., Isaacs W. B., Isaacs J. T. and Gao A. C. (1999): Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res., 59, 2329-2331.
76. Maiti A., Maki G. and Johnson P. (1998): TNF-α induction of CD44-mediated leukocyte adhesion by sulfation. Science, 282, 941-943.
77. Maltzman J. S., Carman J. A. and Monroe J. G. (1996): Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes. Mol. Cell. Biol., 16, 2283-2294.
78. Manicourt D. H., Poilvache P., Nzeusseu A., van Egeren A., Devogelaer J. P., Lenz M. E. and Thonar E. J. (1999): Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum., 42, 1861-1869.
79. McKee C. M., Lowenstein C. J., Horton M. R., Wu J., Bao C., Chin B. Y., Choi A. M. and Noble P. W. (1997): Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor κB-dependent mechanism. J. Biol. Chem., 272, 8013-8018.
80. McKee C. M., Penno M. B., Cowman M., Burdick M. D., Stricter R. M., Bao C. and Noble P. W. (1996): Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J. Clin. Invest., 98, 2403-2413.
81. Menges M., Goebel R., Pueschel W., Zeitz M. and Stallmach A. (2002): Expression of CD44v5 and -v6 in Barrett's carcinoma is not increased compared to that in nondysplastic Barrett's mucosa. Exp. Mol. Pathol., 72, 207-212.
82. Mikecz K., Brennan F. R., Kim J. H. and Glant T. T. (1995): Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis. Nat. Med., 1, 558-563.
83. Mikecz K., Dennis K., Shi M. and Kim J. H. (1999): Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis. Arthritis Rheum., 42, 659-668.
84. Mohamadzadeh M., DeGrendele H., Arizpe H., Estess P. and Siegelman M. (1998): Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J. Clin. Invest., 101, 97-108.
85. Mummert M. E., Mummert D. I., Ellinger L. and Takashima A. (2003): Functional roles of hyaluronan in b16-f10 melanoma growth and experimental metastasis in mice. Mol. Cancer Ther., 2, 295-300.
86. Murakami S., Miyake K., June C. H., Kincade P. W. and Hodes R. J. (1990): IL-5 induces a Pgp-1 (CD44) bright B cell subpopulation that is highly enriched in proliferative and Ig secretory activity and binds to hyaluronate. J. Immunol., 145, 3618-3627.
87. Naor D. and Nedvetzki S. (2003): CD44 in rheumatoid arthritis. Arthritis Res., 5, 105-115.
88. Naor D., Sionov R. V. and Ish-Shalom D. 1997. CD44: structure, function, and association with the malignant process. Adv. Cancer Res., 71, 241-319.
89. Naujokas M. F., Morin M., Anderson M. S., Peterson M. and Miller J. (1993): The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell, 74, 257-268.
90. Neidhart M., Gay R. E. and Gay S. (2000): Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum., 43, 1719-1728.
91. Parish N. M., Brennan F. R. and Cooke A. (1999): Anti-CD44 treatment does not prevent the extravasation of autopathogenic T cells to the thyroid in experimental autoimmune thyroiditis. Immunology, 97, 533-539.
92. Pfister K., Wittig B. M., Mueller-Molaian I., Remberger K., Zeitz M. and Stallmach A. (2001): Decreased CD44v6 expression in lamina propria lymphocytes of patients with inflammatory bowel disease. Exp. Mol. Pathol., 71, 186-193.
93. Ponta H., Sherman L. and Herrlich P. A. (2003): CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol., 4, 33-45.
94. Ponta H., Sleeman J., Dall P., Moll J., Sherman L. and Herrlich P. (1994): CD44 isoforms in metastatic cancer. Invasion Metastasis, 14, 82-86.
95. Protin U., Schweighoffer T., Jochum W. and Hilberg F. (1999): CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J. Immunol., 163, 4917-4923.
96. Pure E., Camp R. L., Peritt D., Panettieri R. A. jr., Lazaar A. L. and Nayak S. (1995): Defective phosphorylation and hyaluronate binding of CD44 with point mutations in the cytoplasmic domain. J. Exp. Med., 181, 55-62.
97. Pure E. and Cuff C. A. (2001): A crucial role for CD44 in inflammation. Trends Mol. Med., 7, 213-221.
98. Rafi-Janajreh A. Q., Chen D., Schmits R., Mak T. W., Grayson R. L., Sponenberg D. P., Nagarkatti M. and Nagarkatti P. S. (1999): Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2. J. Immunol., 163, 1619-1627.
99. Rafi-Janajreh A. Q., Nagarkatti P. S. and Nagarkatti M. (1998): Role of CD44 in CTL and NK cell activity. Front Biosci., 3, D665-671.
100. Reid S. D. and Pockley A. G. (2000): Cytokine regulation of CD44 expression on rat intestinal epithelial cells. Immunol. Invest., 29, 271-286.
101. Reisman D. N., Strobeck M. W., Betz B. L., Sciariotta J., Funkhouser W. jr., Murchardt C., Yaniv M., Sherman L. S., Knudsen E. S. and Weissman B. E. (2002): Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene, 21, 1196-1207.
102. Rosenberg S. A., Lotze M. T., Muul L. M., Leitman S., Chang A. E., Ettinghausen S. E., Matory Y. L., Skibber J. M., Shiloni E., Vetto J. T. and (1985): Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313, 1485-1492.
103. Sato S., Yokozaki H., Yasui W., Nikai H. and Tahara E. (1999): Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line. Jpn. J. Cancer Res., 90, 485-489.
104. Schmits R., Filmus J., Gerwin N., Senaldi G., Kiefer F., Kundig T., Wakeham A., Shahinian A., Catzavelos C., Rak J., Furlonger C., Zakarian A., Simard J. J., Ohashi P. S., Paige C. J. Gutierrez-Ramos J. C. and Mak T. W. (1997): CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood, 90, 2217-2233.
105. Screaton G. R., Bell M. V., Bell J. I. and Jackson D. G. (1993): The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J. Biol. Chem., 268, 12235-12238.
106. Seiter S., Schadendorf D., Tilgen W. and Zoller M. (1998): CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. Clin. Immunol. Immunopathol., 89, 79-93.
107. Shigemori M., Takei S., Imanaka H., Maeno N., Hokonohara M. and Miyata K. (2002): Diagnostic significance of increased serum hyaluronic acid in juvenile rheumatoid arthritis. Pediatr. Int., 44, 394-399.
108. Shtivelman E. and Bishop J. M. (1991): Expression of CD44 is repressed in neuroblastoma cells. Mol. Cell Biol., 11, 5446-5453.
109. Siegelman M. H., DeGrendele H. C. and Estess P. (1999): Activation and interaction of CD44 and hyaluronan in immunological systems. J. Leukoc. Biol., 66, 315-321.
110. Sionov R. V. and Naor D. (1998): Calcium- and calmodulin-dependent PMA-activation of the CD44 adhesion molecule. Cell Adhes. Commun., 6, 503-523.
111. Stallmach A., Wittig B. M., Kremp K., Goebel R., Santourlidis S., Zeitz M., Menges M., Raedle J., Zeuzem S. and Schulz W. A. (2003): Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region. Exp. Mol. Pathol., 74, 262-266.
112. Stamenkovic I., Amiot M., Pesando J. M. and Seed B. (1989): A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell, 56, 1057-1062.
113. Stamenkovic I., Aruffo A., Amiot M. and Seed B. (1991): The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J., 10, 343-348.
114. Stapleton G., Malliri A. and Ozanne B. W. (2002): Downregulated AP-1 activity is associated with inhibition of protein-kinase-C-dependent CD44 and ezrin localisation and upregulation of PKC theta in A431 cells. J. Cell Sci., 115, 2713-2724.
115. Stoop R., Gal I., Glant T. T., McNeish J. D. and Mikecz K. (2002): Trafficking of CD44-deficient murine lymphocytes under normal and inflammatory conditions. Eur. J. Immunol., 32, 2532-2542.
116. Stoop R., Kotani H., McNeish J. D., Otterness I. G. and Mikecz K. (2001): Increased resistance to collagen-induced arthritis in CD44-deficient DBA/1 mice. Arthritis Rheum., 44, 2922-2931.
117. Strobeck M. W., DeCristofaro M. F., Banine F., Weissman B. E., Sherman L. S. and Knudsen E. S. (2001): The BRG-1 subunit of the SWI/SNF complex regulates CD44 expression. J. Biol. Chem., 276, 9273-9278.
118. Takagi T., Okamoto R., Suzuki K., Hayashi T., Sato M., Kurosaka N. and Koshino T. (2001): Up-regulation of CD44 in rheumatoid chondrocytes. Scand. J. Rheumatol., 30, 110-113.
119. Takahashi K., Stamenkovic I., Cutler M., Dasgupta A. and Tanabe K. K. (1996): Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J. Biol. Chem., 271, 9490-9496.
120. Takei S., Imanaka H., Maeno N., Shigemori M., Masuda K., Hokonohara M. and Miyata K. (1996): Serum levels of hyaluronic acid indicate the severity of joint symptoms in patients with systemic and polyarticular juvenile rheumatoid arthritis. J. Rheumatol., 23, 1956-1962.
121. Tammi M. I., Day A. J. and Turley E. A. (2002): Hyaluronan and homeostasis: a balancing act. J. Biol. Chem., 277, 4581-4584.
122. Teder P., Vandivier R. W., Jiang D., Liang J., Cohn L., Pure E., Henson P. M. and Noble P. W. (2002): Resolution of lung inflammation by CD44. Science, 296,155-158.
123. Toyama-Sorimachi N. and Miyasaka M. (1994): A novel ligand for CD44 is sulfated proteoglycan. Int. Immunol., 6, 655-660.
124. Toyama-Sorimachi N., Sorimachi H., Tobita Y., Kitamura F., Yagita H., Suzuki K. and Miyasaka M. (1995): A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J. Biol. Chem., 270, 7437-7444.
125. Tsukada N., Matsuda M., Miyagi K. and Yanagisawa N. (1993): Cytotoxicity of T cells for cerebral endothelium in multiple sclerosis. J. Neurol. Sci., 117,140-147.
126. Verkaik N. S., Trapman J., Romijn J. C., Van der Kwast T. H. and Van Steenbrugge G. J. (1999): Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. Int. J. Cancer, 80, 439-443.
127. Verkaik N. S., Van Steenbrugge G. J., van Weerden W. M., Bussemakers M. J. and Van der Kwast T. H. (2000): Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region. Lab. Invest., 80, 1291-1298.
128. Vial T. and Descotes J. (1995): Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf., 13, 371-406.
129. Wang Q., Teder P., Judd N. P., Noble P. W. and Doerschuk C. M. (2002): CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice. Am. J. Pathol., 161, 2219-2228.
130. Warnock R. A., Askari S., Butcher E. C. and von Andrian U. H. (1998): Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. J. Exp. Med., 187, 205-216.
131. Wayner E. A. and Carter W. G. (1987): Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique α and common β subunits. J. Cell Biol., 105, 1873-1884.
132. Webb D. S., Shimizu Y., Van Seventer G. A. Shaw S. and Gerrard T. L. (1990): LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science, 249,1295-1297.
133. Weber G. F., Ashkar S., Glimcher M. J. and Cantor H. (1996): Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271, 509-512.
134. Weg-Remers S., Anders M., von Lampe B., Riecken E. O., Schuder G., Feifel G., Zeitz M. and Stallmach A. (1998): Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur. J. Cancer, 34, 1607-1611.
135. Weg-Remers S., Ponta H., Herrlich P. and Konig H. (2001): Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J., 20, 4194-4203.
136. Weiss L., Slavin S., Reich S., Cohen P., Shuster S., Stern R., Kaganovsky E., Okon E., Rubinstein A. M. and Naor D. (2000): Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc. Natl. Acad. Sci. USA, 97, 285-290.
137. Wibulswas A., Croft D., Pitsillides A. A., Bacarese-Hamilton I., McIntyre P., Genot E. and Kramer I. M. (2002): Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum., 46, 2059-2064.
138. Wielenga V. J., van der Voort R., Mulder J. W., Kruyt P. M., Weidema W. F., Oosting J., Seldenrijk C. A., van Krimpen C., Offerhaus G. J. and Pals S. T. (1998): CD44 splice variants as prognostic markers in colorectal cancer. Scand. J. Gastroenterol., 33, 82-87.
139. Wittig B., Schwarzler C., Fohr N., Gunthert U. and Zoller M. (1998): Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody. J. Immunol., 161, 1069-1073.
140. Wittig B., Seiter S., Schmidt D. S., Zuber M., Neurath M. and Zoller M. (1999): CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Lab. Invest., 79, 747-759,
141. Wittig B. M., Johansson B., Zoller M., Schwarzler C. and Gunthert U. (2000): Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J. Exp. Med., 191, 2053-2064.
142. Wittig B. M., Stallmach A., Zeitz M. and Gunthert U. (2002): Functional involvement of CD44 variant 7 in gut immune response. Pathobiology, 70, 184-189.
143. Yan P., Muhlethaler A., Bourloud K. B., Beck M. N. and Gross N. (2003): Hypermethylation-mediated regulation of CD44 gene expression in human neuroblastoma. Genes Chromosomes Cancer, 36, 129-138.
144. Zeitz M. (1997): Pathogenesis of inflammatory bowel disease. Digestion, 58 (suppl. 1), 59-61.
145. Zhou D. F., Ding J. F., Picker L. J., Bargatze R. F., Butcher E. C. and Goeddel D. V. (1989): Molecular cloning and expression of Pgp-1. The mouse homolog of the human H-CAM (Hermes) lymphocyte homing receptor. J. Immunol., 143, 3390-3395.